p21: A monitor of p53 dysfunction in ovarian neoplasia

International Journal of Gynecological Cancer

Volumn 7, Issue 4, 1997, Pages 296-303

  Shigemasa, K ^a   Hu, C ^b   West, C M ^a   Moon, S H ^a   Parham, G P ^a   Parmley, T H ^a   Korourian, S ^a   Baker, V V ^b   O'Brien, T J ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

mRNA expression; Mutation status; Ovarian cancer; P21; P53

Indexed keywords

COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE; DNA; MESSENGER RNA; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER STAGING; CELL CYCLE G1 PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTADENOCARCINOMA; CYSTADENOMA; DNA DAMAGE; DNA POLYMORPHISM; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030726771     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1997.00457.x     Document Type: Article

References (29)

1. Boring CC, Squires TS, long T. Cancer Statistics 1992; 42: 19-38.
2. Averette HE, Hoskins W, Nguyen HN, et al. National survey of ovarian carcinoma. Cancer 1993; 71: 1629-38.
3. Hunter T. Cooperation between oncogenes. Cell 1991; 64: 249-70.
4. Bast RC, Boyer CM, Jacobs I. et al. Cell growth retardation in epithelial ovarian cancer. Cancer 1993; 71: 1597-601.
5. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craid RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
6. Shah P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 89: 4495-9.
7. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9.
8. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
9. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
11. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-8.
12. Shinohara M, El-Deiry WS, Wada M, et al. Absence of WAF1 mutation in a variety of human malignancies. Blood 1994; 84: 3781-4.
13. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multi-drug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160-4.
14. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell biol 1986; 6: 1379-85.
15. Hall JL, Dudley L, Dobner PR, Lewis SA, Cowan NJ. Identification of two human β-tubulin isotopes. Mol Cell Biol 1983; 3: 854-62.
16. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-30.
17. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-8.
18. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutation and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 90: 4961-5.
19. Milner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-32.
20. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993; 85: 1513-19.
21. Niwa K, Itoh M, Murase T, et al. Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer 1994; 70: 1191-7.
22. McManus DT, Yap EPH, Maxwell P, Russel SEH, Toner PG, McGee J'OD. p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol 1994; 174: 159-68.
23. Teneriello MG, Ebina M, Linnoila RI, et al. p53 and K-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993; 53: 3103-8.
24. Levine AJ, Perry ME, Chang A, et al. The role of the p53 tumor-suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409-16.
25. Rogel A, Popliker M, Webb CG, Oren M, Webb CG, Oren M. p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos and tumors. Mol Cell Biol 1985; 5: 2851-5.
26. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms a hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-9.
27. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9.
28. Chen J, Marechal, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13: 107-14.
29. Oliner JD, Pietenpol JA, Thiagalingam S, Gyures J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 1993; 632: 857-60.